The ability to manipulate gene expression in speci®c cell types at speci®c times utilizing transgenic technology has allowed the development of novel mouse model systems that can mimic human disease. We have previously established the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) model for prostate cancer using the rat probasin promoter to direct expression of the SV40 early genes to prostate epithelium. Male TRAMP mice exhibit consistent prostatespeci®c patterns of expression and develop prostatic intraepithelial neoplasia that will become invasive and metastasize primarily to the lymph nodes and lungs. In this paper we report our continued experience with this model and present a standardized histologic grading system to designate low and high grade prostatic intraepithelial neoplasia and well, moderate, and poorly differentiated prostate adenocarcinoma. In addition, we demonstrate the persistence of androgen receptor expression during pathologic progression and characterize heterogeneous cytokeratin expression in localized and metastatic prostate cancer. Finally, we report on our observations that phenotypic variability in tumor and pathologic progression in TRAMP occurs as a function of genetic background.
Introduction
Prostate cancer continues to be the most common malignancy detected in American men today. 1 Although frequently detected at earlier stages due to increased public awareness and aggressive screening, 42% of prostate cancers remain undiscovered until they have progressed to regional or distant disease. 1 While the introduction of serum prostate speci®c antigen (PSA) testing has improved the early detection of prostate cancer, new diagnostic tests based on the expression pattern of genes associated with the initiation and progression of prostate cancer are needed to differentiate patients that will not progress from those who may develop more aggressive and metastatic forms of prostate cancer. It is anticipated that development of these new tests will have a signi®cant impact on health care by identifying those prostate cancer patients that require aggressive therapy as early as possible. Therefore, the procurement of specimens representing the earliest stages of prostate cancer of adequate quality for molecular analysis is a priority. To this end, tumor banks have been established as vital resources to facilitate research efforts through the collection of adequate clinical specimens that represent a spectrum of prostate cancer development and progression. 2 It is unfortunate that once premalignant or early prostate cancer samples are obtained, comprehensive molecular studies can be complicated by the histologic and genetic disparity observed within such lesions. For example, it has been demonstrated that the probable histologic precursor of prostate carcinoma prostatic intraepithelial neoplasia (PIN) may display numerous molecular alterations (`hits'). 3 In addition, even regions that histologically appear normal within tumors may frequently carry many of these molecular hits 4 making ostensibly`normal' regions ill suited as adequate control samples for sensitive comparisons of gene expression. Similar disparities have recently been discussed with respect to head and neck squamous cell carcinoma. 5 In addition to the problems associated with the procurement and molecular analysis of clinical specimens from an individual patient, direct comparisons between patients are complicated due to factors including race, 6, 7 and the allelic variations 8 that occur within the human population. Hence, attempts to identify, isolate and characterize sets of clinical specimens representing normal prostate tissue and the full spectrum of prostate cancer, from PIN to androgen independent disease, are constrained by the fact that this is a heterogeneous disease of a heterogeneous population that is frequently detected only after progression to advanced stages. Clearly, these observations underscore the immediate need to develop, characterize and disseminate relevant model systems with de®ned genetic backgrounds that accurately and reproducibly display inherited tendencies toward progressive prostate malignancy.
The ability to directly perturb gene expression in a temporally (for example, induced under speci®c physiologic conditions such as post puberty) and spatially restricted (for example, limited to speci®c target tissues such as prostatic epithelium) fashion in transgenic mice has been facilitated through the identi®cation and characterization of genes that are expressed only in speci®c tissues and the regulatory elements that control their expression. Exploiting these genes and their cognate regulatory regions, it has been possible to develop novel mouse models that can mimic human diseases, including cancer. Unlike subcutaneous transplantable tumor models that try to simulate cancer by propagating tumors in a foreign site, frequently in immune incompetent environments, transgenic models can develop tumors in situ (at the autochthonous site) and in an appropriate physiologic context (stromal Ð epithelial cell interactions) with appropriate blood and lymphatic access. Hence, these models can be employed to characterize the molecular mechanisms responsible for the initiation and progression of cancer in ways not previously possible. One of the most important features of transgenic mouse models that develop autochthonous pathology in a progressive and reproducible fashion is that they provide a virtually inexhaustible source of rapidly renewable research material, particularly tissues that display the earliest of transformation events.
The ability to introduce transgenes into highly inbred and therefore genetically homogenous strains of mice facilitates efforts to elucidate the critical molecular events that may occur during cancer progression. As well, transgenic mouse lines may be bred with various other inbred and outbred strains to identify potential genetic differences that may determine the variability in disease development and progression. Such studies have recently been used to identify the modi®er of min (mom) implicated in colorectal cancer. 9 Furthermore, inbred strains of mice are prerequisite for immunotherapy studies that a priori can not be performed in immune de®cient models. By design, once a transgenic line is established it becomes highly portable and can therefore be distributed to numerous investigators so that independent experiments can be performed on identical animals in various geographical locations making experimental data immediately comparable between laboratories.
We have previously described the development of one autochthonous transgenic animal model of prostate cancer, designated the TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP). The general features of the TRAMP model and other transgenic prostate cancer models have recently been reviewed. 10 Brie¯y, the TRAMP model was generated in a C57BL/6 background utilizing a transgene consisting of a 7426/ 28 bp fragment of the rat probasin (rPB) gene directing the tissuespeci®c expression of simian virus 40 (SV40) early genes (T/t antigens; Tag) to the mouse prostate epithelium to effectively abrogate the activity of the p53 and Rb tumor suppressors in these cells. 11, 12 As a consequence of transgene expressions, TRAMP mice were found to develop epithelial proliferations that became invasive and metastasized primarily to the lymph nodes and lungs. 13 Since the genesis of prostate cancer in the TRAMP model is initially dependent on androgen, castration at 12 weeks of age resulted in an initial decrease in tumor burden, however, overall progression to poorly differentiated and metastatic disease was not ultimately delayed. 14 This unique autochthonous metastatic model of prostate cancer has now been adopted by numerous investigators around the world.
In this paper we report on our continued experience with the TRAMP model and describe a standardized histologic grading system to facilitate consistent pathologic interpretation between investigators. In addition, we present an immunohistochemical characterization of cytokeratin and androgen receptor expression during pathologic progression. Finally, we report our observation using C57BL/6 TRAMP mice and [C57BL/66FVB]F1 TRAMP mice that phenotypic variability in pathologic progression is a function of genetic background, thereby providing supporting evidence for a prostate cancer modi®er gene or gene set.
Materials and methods

Transgenic animals
Previously described male and female TRAMP mice, heterozygous for the PB-Tag transgene, were maintained in a pure C57BL/6 background (Harlan Sprague Dawley, Inc., Indianapolis IN). 11 Transgenic males for these studies were routinely obtained from [C57BL/6 TRAMP female6C57BL/6 non-transgenic male] breeding or as [C57BL/6 TRAMP female6FVB non-transgenic male]F1 offspring. The isolation of mouse tail DNA and PCRbased screening assay were as previously described 11, 15 and detailed protocols can be found online at http:// 128.249.134.198. All experiments were conducted using the highest standards for humane care in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
Preparation and analysis of tissues
Tissues collected at necropsy were routinely ®xed in 10% (vol/vol) phosphate or zinc-buffered formalin for 6 ± 12 h and then transferred to 70% ethanol. Sections (5 mm) were cut from paraf®n-embedded tissues and mounted on ProbeOn-Plus slides (Fisher, Houston TX). Routine histologic sections were stained with hematoxylin and eosin.
Immunohistochemical methods for T antigen oncoprotein were as previously described. 14 Immunostaining for high molecular weight cytokeratins was performed using pancytokeratin antibody Z0622 (Dako, Carpinteria CA) as previously described. 16 Androgen receptor antibody PG-21 was a gift from Dr G Prins (University of Illinois, Chicago, IL) and used at a 1 : 500 dilution following microwave antigen retrieval in 0.01 M citric acid as reported previously. 17 Immunoreactive species were visualized using the Vectastain Elite ABC immunoperoxidase system according to the manufacturers recommended protocols (Vector Laboratories, Burlingame, CA). Tissues were counterstained with either a weak methyl green stain for cytokeratin immunohistochemistry or hematoxylin stain for androgen receptor immunohistochemistry.Results and discussion
Grading system
Whereas the human prostate consists of a single organ, the rodent prostate is composed of four paired glands: the dorsal, lateral, ventral and anterior prostate or coagulating gland ( Figure 1A ± D) . Each of the glands contains acini that are composed of a singular layer of columnar secretory epithelium with rounded basal nuclei. Nucleoli are frequently prominent in the normal mouse prostate epithelium. Each acinus is surrounded by 3 ± 4 layers of ®bromuscular stromal ®broblasts and smooth muscle cells. In contrast to the human prostate, there is relatively little ®bromuscular stroma between glands in the mouse.
The ventral prostate contains acini that are composed of a singular layer of somewhat taller columnar secretory epithelium with rounded, basal nuclei ( Figure 1E ). The secretions are generally less eosinophilic and less uniform than the dorsolateral or anterior prostate. The anterior prostate is characteristically composed of a single layer of secretory epithelium that is cuboidal with numerous infoldings and light pink secretions ( Figure 1F ). It should be noted that the appearance of the lumenal secretions, although somewhat characteristic in color and consistency between lobes, is not a completely reliable indicator of the speci®c region of the prostate. In fact, reliable histologic comparisons between lobes of the prostate can only be determined through meticulous anatomical dissections at the time of necropsy or through utilization of additional immunohistochemical staining for proteins unique to particular lobes of the prostate. 18 The prostate glands can be readily distinguished histologically from the seminal vesicles that characteristically display a more prominent ®bromuscular stroma with granular lumenal secretions ( Figure 1G ) and from the ampullary glands that display a more prominent ®bro-muscular stroma with`Swiss cheese' like secretions ( Figure 1H ).
All TRAMP males are similarly predisposed to prostate cancer as a consequence of the inherited PB-Tag transgene that is expressed primarily in the dorsolateral and ventral lobes of the prostate, with relatively minor expression in the anterior prostate and seminal vesicles. 15 However, we have observed some phenotypic variability in TRAMP that appears to arise in a stochastic fashion. As early as 4 ± 6 weeks of age, changes in nuclear size and nuclear elongation may be observed within scattered regions of prostatic acini of the ventral and dorsolateral prostate consistent with that observed in human low grade PIN (Table 1, Figure 2A ). These regions generally express immunoreactive T antigen oncoprotein. 13 Scarce foci of immunohistochemical T antigen expression have also been observed in the anterior prostate (data not shown). At this stage, immunohistochemistry demonstrates predominantly nuclear androgen receptor in the epithelial and stromal cells but not in the basal epithelial cells that characteristically do not express immunoreactive AR ( Figure 2B ) in agreement with previously published reports. 19 By 6 ± 10 weeks of age, epithelial strati®cation is increased in the dorsolateral prostate of TRAMP males. Typically, cribriform high grade PIN ( Figure 2C ) and tufted, micropapillary, and¯at patterns of high grade PIN are observed ( Figure 2D ). At this stage, nuclear chromatin becomes increasingly dense and clumped and numerous mitotic ®gures and apoptotic bodies are usually present ( Figure 2D ). The androgen receptor remains localized primarily within the compacted nucleus ( Figure 2E ). By the time TRAMP males reach the age of 10 ± 16 weeks, high grade PIN is generally present throughout the majority of the dorsolateral prostatic acini. At this time, invasion of epithelial cells through the thin ®bromuscular stroma consistent with well differentiated prostate adenocarcinoma may be observed ( Figure 2F ). These invading cells frequently retain high molecular weight cytokeratin expression which is often lost later in progression ( Figure 2G ). As demonstrated in Figure 2H , the androgen receptor is strongly localized to the nucleus. Interestingly, this progression to high grade PIN and invasive carcinoma is not generally prominent in the ventral prostate or anterior prostate. It is important to note that the relatively normal lobes of the ventral prostate may frequently be found engulfed within large dorsolateral prostate tumors even at several months of age (data not shown).
We have reproducibly observed that between the ages of 10 ± 16 weeks the ®bromuscular stroma appears to become hyperplastic and hypertrophied with increasing numbers of visible rounded nuclei ( Figure 3A) . This was more commonly observed than frank epithelial cell invasion. Many of the rounded nuclei within the thickened ®bromuscular stroma demonstrate immunoreactive T antigen oncoprotein consistent with epithelial cell invasion ( Figure 3B ). We have also designated this pathology as well differentiated prostate cancer since the glandular architecture, along with the underlying stroma, is maintained. Tumors that demonstrate packed and irregularly shaped glands were classi®ed as moderately well differentiated ( Figure 3C ). Note that numerous ®gures are generally present at this stage ( Figure 3C. ).
Tumors composed of sheets of cells with little or no glandular formation were classi®ed as poorly differentiated ( Figure 3E ) and vascular invasion was readily apparent ( Figure 3E ). Metastases to the peri-aortic lymph nodes were present in approximately 19% of mice by the age of 18 ± 24 weeks. 14 Occasionally, lymphatic metastases were observed to maintain expression of high molecular weight cytokeratins, consistent with their epithelial origin. Interestingly, hepatic metastases more frequently maintained persistent cytokeratin expression, but in general, these lesions occurred less often than lymphatic and lung metastases. Metastatic lesions were seen infrequently in the spinal column, kidney, and adrenal gland. 13, 20 
Strain variation
As previously published reports demonstrated that oncogene-mediated transformation of C57BL/6 prostate epithelium could result in metastatic disease 21 the TRAMP model was established from C57BL/6 PB-Tag founder mouse #8247. 11, 13 In addition, it was anticipated It is tempting to speculate on how strain differences between the C57BL/6 and the [TRAMP6FVB]F1 mice could account for the phenotypic variability observed in these studies. One possibility is that the angiogenic switch occurs earlier in the hybrid mice based on the grossly increased vascularity of the [TRAMP6FVB]F1 tumors. Alternatively, allelic variation in the expression of growth factors or tumor suppressor genes could account for the differences observed in tumor development and progression. Given the highly reproducible development of spontaneous autochthonous prostate cancer in the TRAMP model, it should be possible to obtain suf®cient materials representing all stages of prostate cancer progression for the studies now in progress to further investigate each of these possibilities.
Conclusions
TRAMP mice represent a genetically de®ned paradigm in which to investigate the stochastic molecular progression of prostate cancer from PIN through well differentiated localized disease to invasive and metastatic androgen independent cancer. Given the ability of TRAMP to generate a highly reproducible and virtually inexhaustible supply of specimens representing each stage of prostate cancer progression with appropriate controls, the characterization of genetic alterations during pathologic progression and allelic differences accounting for observed phenotypic variability may help to predict aggressive human pathologic progression from latent to clinically signi®cant disease. It is anticipated that identi®cation of speci®c molecular events leading to the progression of prostate cancer in the TRAMP model may provide a means to distinguish those patients who require and would bene®t most from early aggressive therapy. 
